Toll Free: 1-888-928-9744

CSL Limited - Product Pipeline Review - 2015

Published: Oct, 2015 | Pages: 78 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

CSL Limited - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'CSL Limited - Product Pipeline Review - 2015', provides an overview of the CSL Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CSL Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of CSL Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of CSL Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the CSL Limited's pipeline products

Reasons to Buy

- Evaluate CSL Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of CSL Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the CSL Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of CSL Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of CSL Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of CSL Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents
2 List of Tables 6 List of Figures 6 CSL Limited Snapshot 7 CSL Limited Overview 7 Key Information 7 Key Facts 7 CSL Limited - Research and Development Overview 8 Key Therapeutic Areas 8 CSL Limited - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Pipeline Products - Combination Treatment Modalities 13 Pipeline Products - Partnered Products 14 Partnered Products/Combination Treatment Modalities 15 Pipeline Products - Out-Licensed Products 16 Out-Licensed Products/Combination Treatment Modalities 17 CSL Limited - Pipeline Products Glance 18 CSL Limited - Late Stage Pipeline Products 18 Pre-Registration Products/Combination Treatment Modalities 18 Filing rejected/Withdrawn Products/Combination Treatment Modalities 19 Phase III Products/Combination Treatment Modalities 20 CSL Limited - Clinical Stage Pipeline Products 21 Phase II Products/Combination Treatment Modalities 21 Phase I Products/Combination Treatment Modalities 22 CSL Limited - Early Stage Pipeline Products 23 Preclinical Products/Combination Treatment Modalities 23 Discovery Products/Combination Treatment Modalities 24 CSL Limited - Drug Profiles 25 albutrepenonacog alfa 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 antihemophilic factor (recombinant) 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 haemophilus influenzae [serotype B] vaccine 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 seasonal influenza (quadrivalent) vaccine 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 (prothrombin + coagulation factor VII human + coagulation factor IX human + coagulation factor X human + protein C + protein S human) 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 C1 esterase inhibitor (human) 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 CSL-689 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 CSL-112 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 CSL-311 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 factor XIII (human) 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 influenza [strain H5N1] vaccine 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 seasonal influenza (trivalent) vaccine 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 influenza [strain A/H3N2] (monovalent) vaccine 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 influenza [strain H7N9] (monovalent) vaccine 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 2H-10 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 CSL-312 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 CSL-324 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 CSL-346 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 CSL-650 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Drug for Undisclosed Indication 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Monoclonal Antibody for Hematological Disorders 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Monoclonal Antibodies for Undisclosed Indication 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 PODCRC-OHS 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Proteins for Undisclosed Indication 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Recombinant Protein for Hemophilia 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 CSL Limited - Pipeline Analysis 58 CSL Limited - Pipeline Products by Target 58 CSL Limited - Pipeline Products by Route of Administration 59 CSL Limited - Pipeline Products by Molecule Type 60 CSL Limited - Pipeline Products by Mechanism of Action 61 CSL Limited - Recent Pipeline Updates 62 CSL Limited - Dormant Projects 72 CSL Limited - Company Statement 73 CSL Limited - Locations And Subsidiaries 74 Head Office 74 Other Locations & Subsidiaries 74 Appendix 77 Methodology 77 Coverage 77 Secondary Research 77 Primary Research 77 Expert Panel Validation 77 Contact Us 77 Disclaimer 78
List of Tables
CSL Limited, Key Information 7 CSL Limited, Key Facts 7 CSL Limited - Pipeline by Indication, 2015 9 CSL Limited - Pipeline by Stage of Development, 2015 11 CSL Limited - Monotherapy Products in Pipeline, 2015 12 CSL Limited - Combination Treatment Modalities in Pipeline, 2015 13 CSL Limited - Partnered Products in Pipeline, 2015 14 CSL Limited - Partnered Products/ Combination Treatment Modalities, 2015 15 CSL Limited - Out-Licensed Products in Pipeline, 2015 16 CSL Limited - Out-Licensed Products/ Combination Treatment Modalities, 2015 17 CSL Limited - Pre-Registration, 2015 18 CSL Limited - Filing rejected/Withdrawn, 2015 19 CSL Limited - Phase III, 2015 20 CSL Limited - Phase II, 2015 21 CSL Limited - Phase I, 2015 22 CSL Limited - Preclinical, 2015 23 CSL Limited - Discovery, 2015 24 CSL Limited - Pipeline by Target, 2015 58 CSL Limited - Pipeline by Route of Administration, 2015 59 CSL Limited - Pipeline by Molecule Type, 2015 60 CSL Limited - Pipeline Products by Mechanism of Action, 2015 61 CSL Limited - Recent Pipeline Updates, 2015 62 CSL Limited - Dormant Developmental Projects,2015 72 CSL Limited, Other Locations 74 CSL Limited, Subsidiaries 74



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify